Navigating the Complexities of a Pharmacy Acquisition

Years ago, an ailing company like Walgreens Boots Alliance may have seemed like a prime acquisition target for deal-hungry private equity firms. But many have backed away from retail recently, leaving an opening for groups like Sycamore Partners who are willing to buck the trend. Sycamore announced this month that it would take the global pharmacy business private in a $23.7bn debt and equity deal. The FT’s Due Diligence reporter, Amelia Pollard, explains the well-worn playbook that Sycamore has used on past retail companies, and whether it will work this time with a chain that has its own share of unique problems.  

Clips from Bloomberg, CNBC, CBS

- - - - - - - - - - - - - - - - - - - - - - - - - - 

For further reading:

Retail’s last barbarian: the private equity group about to play hardball with Boots

What went wrong after Walgreens bought Boots? 

Walgreens bondholders could be winners from its debt-laden buyout

- - - - - - - - - - - - - - - - - - - - - - - - - - 

Follow Amelia Pollard (@ameliajpollard) on X or (@pollard.bsky.social) on Bluesky. Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. 

For more from Amelia and her team, sign up for the Due Diligence newsletter. 

Read a transcript of this episode on FT.com

Hosted on Acast. See acast.com/privacy for more information.